224 related articles for article (PubMed ID: 31715513)
21. Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.
Akin-Akintayo OO; Jani AB; Odewole O; Tade FI; Nieh PT; Master VA; Bellamy LM; Halkar RK; Zhang C; Chen Z; Goodman MM; Schuster DM
Clin Nucl Med; 2017 Jan; 42(1):e22-e28. PubMed ID: 27749412
[TBL] [Abstract][Full Text] [Related]
22. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
[No Abstract] [Full Text] [Related]
23. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
24.
Rais-Bahrami S; Efstathiou JA; Turnbull CM; Camper SB; Kenwright A; Schuster DM; Scarsbrook AF
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):997-1006. PubMed ID: 34012062
[TBL] [Abstract][Full Text] [Related]
25. [
Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
[TBL] [Abstract][Full Text] [Related]
26. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
27. Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (
Bhanvadia RR; Woldu SL; Margulis V; Subramaniam RM; Bagrodia A
Clin Genitourin Cancer; 2019 Feb; 17(1):e184-e186. PubMed ID: 30454969
[No Abstract] [Full Text] [Related]
28. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
29. 18F-Fluciclovine-Avid Pulmonary Hamartoma.
Baldeosingh SC; Rowe SP; Greco SC; Paller CJ; Goel R
Clin Nucl Med; 2021 Nov; 46(11):919-921. PubMed ID: 34582137
[TBL] [Abstract][Full Text] [Related]
30. Laparoscopic Port-Site Metastasis From Prostate Cancer on 18F-Fluciclovine PET/CT.
Tran G; Parrinello D; Dalal I
Clin Nucl Med; 2021 May; 46(5):e279-e281. PubMed ID: 33208626
[TBL] [Abstract][Full Text] [Related]
31. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
32. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
33. Prostate Cancer Local Recurrence Detected With Both
Gorin MA; Pienta KJ; Pomper MG; Rowe SP
Urology; 2017 Sep; 107():e9-e10. PubMed ID: 28641974
[TBL] [Abstract][Full Text] [Related]
34. Best Practices for
Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
[No Abstract] [Full Text] [Related]
35. Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT.
Baiomy A; Martiniova L; Efstathiou E; Schuster DM; Ravizzini G
Clin Nucl Med; 2021 Apr; 46(4):e240-e241. PubMed ID: 33208612
[TBL] [Abstract][Full Text] [Related]
36. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
37. Impact of
Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
[TBL] [Abstract][Full Text] [Related]
38. ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer.
Savir-Baruch B; Banks KP; McConathy JE; Molchanova-Cook OP; Parent EE; Takalkar A; Tulchinsky M; Yu JQ; Subramaniam RM; Schuster DM
Clin Nucl Med; 2018 Dec; 43(12):909-917. PubMed ID: 30325827
[TBL] [Abstract][Full Text] [Related]
39. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
40. Prospective Clinical Trial of
Ulaner GA; Goldman DA; Corben A; Lyashchenko SK; Gönen M; Lewis JS; Dickler M
J Nucl Med; 2017 Jul; 58(7):1037-1042. PubMed ID: 27856630
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]